Compare ITCI & KBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
KBR (formerly Kellogg, Brown & Root) is global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: government solutions and sustainable technology solutions. KBR has operations in over 30 countries, and employs approximately 34,000 people. The firm generated $7 billion in revenue in 2023.